Generic Drug Review June 2019

Biosimilars: Not Simply Generics

With the entry of biosimilars into the U.S. market, it is important for pharmacists to understand these products and how they differ from generic medications.

FDA Update on Recent Voluntary ARB Drug Recalls

Recent voluntary recalls of certain angiotensin II receptor blockers have heightened scrutiny of the non-U.S. manufacturing of drugs marketed in the U.S. and of FDA oversight of the process.